With its proprietary formulation technology, Orexo has developed four innovative products from idea to patient. Patients´needs have always been central in development, and they are also is of great importance when the future oral and sublingual formulation technologies are being developed to improve drugs within the therapeutic area of addiction.

 

Oral formulation technology

Many active ingredients face major challenges when administered by the oral route. For example, incomplete dissolution in the GI-tract, poor intestinal absorption and extensive metabolism may all limit the bioavailability. Consequently, many drugs are not effective when administered orally. Orexo is currently developing a new formulation technology that can overcome these issues, thereby en- abling oral administration of drugs for which this route is not feasible today. Several active ingredients have been identified as promising candidates for this technology.

One project that is based on this new technology is OX382 which is an oral formulation of buprenorphine. The aim is to be first to market in this new product class and to offer clear benefits over today’s treatment options for certain patient categories and treatment settings.

Sublingual formulation technology

The sublingual space represents numerous opportunities as well as challenges for the delivery of drugs. Sublingual products need to be well tolerated by patients and properties such as taste and mouth feel are critical for successful treatment. Furthermore, the amount of saliva available under the tongue is limited, which makes significant demands of the formulation in order to act efficiently.

Orexo is recognized as a world leader in the development of efficient sublingual products. Zubsolv®, Abstral® and Edluar® all utilize Orexo’s proprietary sublingual formulation platform based on interactive mixture principles, providing rapid onset and efficient absorption of the drug across the sublingual mucosa.

In Zubsolv, this concept has been further refined, resulting in a product with highly efficient absorption across the sublingual mucosa. This enabled the development of a product with significantly improved efficiency compared with those of competitors.

Orexo is currently developing its second-generation sublingual formulation technology. The aim is to perfect the sublingual delivery of drugs, thereby unlocking new active ingredients that are currently not possible to administer sublingually. Several active ingredients have been identified as promising candidates for this technology.